Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098201 · ClinicalTrials.gov registry record
Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 5
- Enrollment target
NCT01098201: Completed study, sponsored by University of Rochester.
NCT01098201 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01098201 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This open-label pilot study will select subjects who are inadequate responders to methotrexate. These subjects will receive certolizumab subcutaneously on a monthly basis for six months. The study is attempting to determine the following: 1. Is lymphatic flow altered in the extremities of RA patients with an inflamed knee? 2. Is resolution of synovitis associated with a restoration of lymphatic flow and lymph node volume following therapy with certolizumab? 3. Can Doppler ultrasound be used to detect and follow alterations of lymph node size?
Primary Outcome
To examine the lymph flow in the knee joint of RA patients before therapy with certolizumab using technetium sulfur colloid scans, MRI and Doppler ultrasound.
Interventions
- DRUG Certolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-07 |
What the finished NCT01098201 record still lists
NCT01098201 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab is the first listed.
NCT01098201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01098201 about?
NCT01098201 is a clinical study titled "Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)". This open-label pilot study will select subjects who are inadequate responders to methotrexate. These subjects will receive certolizumab subcutaneously on a monthly basis for six months. The study is attempting to determine the following: 1. Is lymphatic flow altered in the extremities of RA patien...
What is the current status of trial NCT01098201?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01098201?
The interventions under investigation include: Certolizumab (DRUG).
Who is sponsoring clinical trial NCT01098201?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia